Status:
RECRUITING
Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
National Research Agency, France
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50-90 years
Phase:
NA
Brief Summary
BioCogBankAD aims at building a prospective clinical practice cohort of 244 patients with biologically confirmed mild cognitive impairment due to Alzheimer's Disease (AD) or mild AD in order to valida...
Detailed Description
Alzheimer's disease (AD) is a leading cause for individual and caregiver burden associated with neurodegenerative diseases (NDs) in an aging population, afflicting + 35 million people worldwide, and s...
Eligibility Criteria
Inclusion
- Diagnosis of AD according to IWG-2 2014 criteria
- Age 50-90 year old
- Affiliated or beneficiary of a social security scheme
- MMSE ≥ 20
- Abnormal CSF Aβ42 or Aβ40/Aβ42 ratio according to local cut-offs
- Abnormal CSF phosphorylated and total Tau according to local cut-offs
- Ability to pass neuropsychological assessments
- Availability of a brain MRI with T1 volumetric sequence performed within 1 year
Exclusion
- Other cause of dementia
- Participation in an AD therapeutic clinical trial
- Protected adults (including individual under guardianship by court order),
Key Trial Info
Start Date :
October 31 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
244 Patients enrolled
Trial Details
Trial ID
NCT06582199
Start Date
October 31 2024
End Date
September 1 2027
Last Update
January 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Cochin
Paris, France, 75014